Industry professionals fear job losses

by Admin 13. February 2012 14:37

 Nearly half of professionals working within the pharmaceutical industry fear being made redundant in the next 12 months, a new report has found.

Pharma IQ’s The Big Pharma Recession Survey 2011 revealed that 44.4% of respondents feared the axe with those working within the US and European markets believing they are most at risk.

The report, conducted at the end of last year, assessed how the global economy is directly impacting professionals working within the industry and discovered their expectations in 2012.

Unsurprisingly it found that the US and Europe are the two regions which respondents feel have been affected the most by the global economic crisis. The report found that the Emerging Markets in the east appear to be the least affected region with 7.3% of participants identifying this region as being the worst hit.

More than two-thirds of respondents (71.2%) agreed that the global pharmaceutical industry is undergoing a dramatic change due to the recession which has swept the globe. Research and development divisions have been impacted the most, 37.9% of respondents said, followed by sales and marketing (30.7%), manufacturing (11.2%), clinical (10.8%), regulatory affairs (3.6%), IT (3.2%) and distribution (2.6%).

After witnessing widespread job losses within the industry in recent years, almost half of respondents (47.5%) said that the industry is ill-prepared to deal with a double-dip recession.

But participants did expect to see an increase in outsourcing and offshoring as pharma searches for new models to combat price reductions and global austerity measures.

“All companies must remain profitable to survive and the pharmaceutical industry is no different,” said Andrea Charles, Editor, Pharma IQ. “As economic landscapes change, pharmaceutical companies must find new models for growth and profitability in 2012 and beyond.”

Pharma deals down in 2011

by Admin 30. January 2012 15:36

 Deal-making activity fell by nearly a fifth last year as pharmaceutical companies reduced R&D expenditure and streamlined their activities, research has shown.

PharmaVentures found that overall deals were down by 18% in 2011 and licensing arrangements fell by 16%. However, M&A activity increased by 30% as companies sought to secure their futures.

Fintan Walton, Chief Executive of PharmaVentures, said the industry is “undergoing a rapid and major transformation” but there was still “significant opportunity for great deals to be done”.

Research focused on PharmaVentures’ database, records and working relationships from within the pharmaceutical industry. It revealed that although merger deals were on the rise, so too were the contingency payments included in recent deals.

Oncology was the most popular therapeutic area to dominate the landscape with Roche being the most prolific deal-maker.

Unsurprisingly, pharmaceutical companies turned to Emerging Markets – particularly China and India – to conduct the majority of their deals. AstraZeneca recently completed a deal to acquire Guangdong BeiKang Pharmaceutical, a manufacturer of generic injectable antibiotics, to strengthen its position in the region. Bayer HealthCare also increased its presence in India last year when it partnered with Zydus Cadila after Merck had created a similar venture with Sun Pharmaceutical Industries.

PharmaVentures is an international healthcare advisory group.


Tag cloud


<<  May 2018  >>

View posts in large calendar

Month List